Finally, Defactinib (VS-6063), a potent dual FAK/PYK2 inhibitor, has successfully transitioned to Phase I and II trials after demonstrating promising preclinical results such as reducing tumor weight and enhancing chemosensitivity [23,24]. Here, PTK2B is linked to neoplasm.